Biomarkers
Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers
Current Oncology 2026 February 3 [Link] Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano Abstract Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum-pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous,…
Read MoreClinical Importance of Molecular Biomarkers in Pleural Mesothelioma
Cancers 2026 February 19 [Link] Logan Roof, Kenna Koehler, Claire Verschraegen Abstract Pleural mesothelioma (PM) is a rare malignancy with opportunities for improvement in current treatment paradigms despite recent advances in systemic therapy. While histology remains the most clinically relevant prognostic indicator, the expanding use of immunotherapy and ongoing clinical trials involving targeted therapies have…
Read MoreFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Journal of Clinical Oncology 2026 March 20 [Link] Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Nobukazu Fujimoto, Solange Peters, Aaron S Mansfield, Sanjay Popat, Yolanda Bautista Aragon, Toby Talbot, Francesco Grossi, Dariusz Kowalski, Muhammet A Kaplan, Andrés Felipe Cardona, Raheela Soomro, Nan Hu, Adam Lee, Virginia Ip, Yu-Han Hung, Gérard Zalcman Abstract…
Read MoreMoving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma
Journal of Thoracic Oncology 2026 February 20 [Link] Gabrielle Drevet, Lipika Kalson, Laurane Mangé, Francoise Galateau-Salle, Arnaud Scherpereel, Lara Chalabreysse, Julien Mazières, Luka Brcic, Nicolas Alcala, Jean-Michel Maury, Lynnette Fernandez-Cuesta, Matthieu Foll Abstract Despite recent advances in the treatment of pleural mesothelioma, it remains a challenging and heterogeneous disease, with limited options for patients. Survival…
Read MoreA proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts
Clinical and Experimental Medicine 2026 February 20 [Link] Elton Jalis Herman, Alessandra Allione, Clara Viberti, Marcello Manfredi 2, Alessia Russo, Khadija Sana-Hafeez, Nina Kaiser, Georg Johnen, Thomas Brüning, Dario Mirabelli, Irma Dianzani, Antonio Agudo, Elisabete Weiderpass, Vittorio Simeon, Rudolf Kaaks, Renée Turzanski-Fortner, Rosario Tumino, Lorenzo Milani, José María Gálvez-Navas, Matthias B Schulze, Catarina Schiborn, Natalia…
Read MoreThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma
Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, the major cause of which is asbestos exposure. Adjuvant radiotherapy after pleurectomy/decortication (P/D) aims at…
Read MoreNeoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases
The American Journal of Case Reports 2026 February [Link] Arnaldo Urbano-Ruiz, Bruna Latronico Palma, Ronaldo Elias Carnut Rego, Daniel Bianqui Guaraldo da Silva, Bianca Fava, Erlan Araujo Falcão , Michelle Louise Rodrigues Barbosa da Silva, Julia Rodrigues Leandro Uliano Abstract BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The…
Read MorePD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma
Cells 2026 January 19 [Link] Milija Gajić, Vesna Ćeriman Krstić, Natalija Samardžić, Ivan Soldatović, Sofija Glumac, Milena Jovanović 4, Milan Savić, Mihailo Stjepanović, Spasoje Popević, Ruža Stević, Nikola Čolić, Katarina Lukić, Vladimir Milenković, Ivan Milivojević, Ivana Sekulović Radovanović, Dragana Jovanović Abstract Malignant pleural mesothelioma (MPM) is a very aggressive tumor. The prognostic value of PD-L1…
Read MorePrognostic value and clinical significance of tumoral PD-L1 and stromal α-SMA expression in diffuse pleural mesothelioma
Neoplasma 2026 February [Link] Yeqi Sun, Lan Li, Lei Cai, Jihua Yang, Jun Qian, Fajiu Wang, Lifeng Wang Abstract Diffuse pleural mesothelioma (PM) is a rare malignant neoplasm with an extremely poor prognosis. Prognostic assessment remains challenging, highlighting the urgent need for reliable biomarkers to guide precise and effective therapy. Programmed death ligand 1 (PD-L1)…
Read MoreMulti-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations
Lung Cancer 2026 February [Link] Kathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, Elly Marcq, Adrian Covaci, Ken Op de Beeck, Jan P van Meerbeeck, Jo Raskin, Annelies Janssens, Annemiek Snoeckx, Kevin Lamote Abstract Objectives: Pleural mesothelioma (PM) is an aggressive thoracic cancer related to historical exposure to asbestos fibres. Symptoms often appear at an advanced stage,…
Read More
Skip to content